Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab Endoscopy Trial to Evaluate the Effects on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jul 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms EXTEND
- Sponsors Abbott Laboratories
- 23 May 2021 Results of post-hoc and pooled analysis from NCT01369329, NCT01369342, NCT01369355 and NCT02096861 developing validate a modified multiplier of the SES-CD (MM-SES-CD) as a Predictior of Endoscopic Remission in Crohns Disease, presented at the Digestive Disease Week 2021
- 07 Mar 2018 Results of pooled data from 11 induction, maintenance and open-label extension studies of adalimumab, were published in the Advances in Therapy.
- 27 Jan 2018 Results assessing the safety of Adalimumab Dosed Every Week and Every Other Week in patients from this and 12 other studies, published in the American Journal of Clinical Dermatology.